Lund­beck out-li­cens­es three can­di­dates to Cam­bridge biotech

Lund­beck is out-li­cens­ing three can­di­dates to Neu­ro3 Ther­a­peu­tics, a two-year-old biotech based in Cam­bridge — and giv­ing it­self an op­tion to li­cense back those rights in cer­tain ter­ri­to­ries.

Ac­cord­ing to Mon­day’s an­nounce­ment, the deal gives Neu­ro3 one pre­clin­i­cal and two clin­i­cal-stage can­di­dates, all of which tar­get and ac­ti­vate KC­NQ2, an ion chan­nel. The com­pa­nies said Lund­beck can choose to de­vel­op and com­mer­cial­ize the can­di­dates along­side Neu­ro3 af­ter proof-of-con­cept.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER